BRS5-2-6 - Polyphenol Biotransformation & Mitochondrial-Relevant Metabolite Generation
1. Mission & Overview
Mission
Enable microbial activation of dietary polyphenols into bioactive metabolites.
Intervention Dominance: Diet-Supported — Dietary Requirements
-
Epicatechin
-
Ellagic acid
-
Ellagitannins
No additional separately disclosed biochemical participants established; independently adjudicated biochemical roles remain in the atoms above.
No mapping established.
Overview
Gut microbes can convert some dietary polyphenols into different metabolites. Ellagitannins release ellagic acid, from which cooperating microbes can form urolithins. Not everyone completes this conversion to urolithin A. Understanding that variability separates microbial processing from taking the finished metabolite as a supplement. [5]
- Benefits: Microbial conversion can make metabolites available for downstream biology. Human mitochondrial findings after direct urolithin A administration do not prove benefit from foods or improved microbial conversion.
- Implementation Notes: Ellagic acid and its ellagitannin precursors provide the studied route’s substrate. Food matrix and microbial conversion capacity matter; direct urolithin A bypasses this mechanism.
- Biological Relevance: Do not generalise the ellagic-acid route to all polyphenols, tea, cocoa or plant diversity. Downstream mitophagy evidence must retain its administered-metabolite exposure.
2. Primary Biological Effects
- Ellagic acid conversion requires microbial activity; particular species perform intermediate steps, and human completion varies. [5]
- Administered urolithin A has downstream mitochondrial and experimental cognition findings. [1]
3. Intervention Levers
No separately adjudicated practice is admitted in this assessment. This is not evidence that no practice can affect the mechanism.
No separately adjudicated lifestyle lever is admitted in this assessment.
4. Mechanistic Basis
Summary
Ellagic acid conversion requires microbial activity; particular species perform intermediate steps, and human completion varies. [5]
Biological process
Ellagic acid and ellagitannin provision support the route. A finished-metabolite supplement does not assess that conversion. [5]
Mechanism Boundary
Do not generalise the ellagic-acid route to all polyphenols, tea, cocoa or plant diversity. Downstream mitophagy evidence must retain its administered-metabolite exposure.
Integration
This PM contributes its specific process to its parent FM. Shared inputs do not merge distinct jobs or prove an integrated clinical outcome.
4.1 Scientific Findings (3)
Summary
Culture studies identify partial ellagic-acid conversion by particular bacteria. Human pomegranate exposure shows substantial variation in urolithin A generation. Direct urolithin A studies preserve downstream evidence but bypass the microbial step. [5] [2] [1] [3]
Ellagic acid conversion requires microbial activity; particular species perform intermediate steps, and human completion varies.
What this means
Ellagic acid and ellagitannin provision support the route. A finished-metabolite supplement does not assess that conversion.
Evidence confidence: Not yet scored
Finding ID: PM6-F1
Finding Statement: Ellagic acid conversion requires microbial activity; particular species perform intermediate steps, and human completion varies.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Ellagic acid and ellagitannin provision support the route. A finished-metabolite supplement does not assess that conversion.
Synthesis Limitations: Species participation does not establish that those species alone form urolithin A or that all people convert food exposures similarly.
Evidence Considered:
- Study
- Two human intestinal Gordonibacter species cultured with ellagic acid.
- Population
- Two human intestinal Gordonibacter species cultured with ellagic acid.
- Result
- The species converted ellagic acid into intermediate urolithins.
- Effect / Magnitude
- Only extracted comparisons retained; no pooled effect or clinical-benefit magnitude assigned.
- Evidence Summary
- The species converted ellagic acid into intermediate urolithins.
- Limitations
- They did not establish complete urolithin A production by the two species alone.
- Evidence Source
- Bounded external search
- Reference
- [5]
- Study
- Pomegranate juice compared with direct urolithin A in healthy adults.
- Population
- Pomegranate juice compared with direct urolithin A in healthy adults.
- Result
- Food-derived urolithin A exposure varied, while direct administration bypassed conversion and increased exposure.
- Effect / Magnitude
- Only extracted comparisons retained; no pooled effect or clinical-benefit magnitude assigned.
- Evidence Summary
- Food-derived urolithin A exposure varied, while direct administration bypassed conversion and increased exposure.
- Limitations
- A studied juice matrix is not proof of equivalent conversion from every ellagitannin food or constituent.
- Evidence Source
- Bounded external search
- Reference
- [2]
Connected / Supportive Evidence:
- Schleupner and Carmichael (2022) [4]Why relevant: Attached corpus assessed for connection to this PM; preserved in the draft evidence inventory.Why excluded from the primary synthesis: Research-design context; no PM-specific intervention or mechanism measurement.
Administered urolithin A has downstream mitochondrial and experimental cognition findings.
What this means
Preserve those measured effects while separating them from PM6 conversion efficacy.
Evidence confidence: Not yet scored
Finding ID: PM6-F2
Finding Statement: Administered urolithin A has downstream mitochondrial and experimental cognition findings.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Preserve those measured effects while separating them from PM6 conversion efficacy.
Synthesis Limitations: Human molecular endpoints and animal cognition are not human food-to-cognition evidence.
Evidence Considered:
- Study
- Direct urolithin A administration in older adults.
- Population
- Direct urolithin A administration in older adults.
- Result
- Mitochondrial molecular signatures changed after administered metabolite exposure.
- Effect / Magnitude
- Only extracted comparisons retained; no pooled effect or clinical-benefit magnitude assigned.
- Evidence Summary
- Mitochondrial molecular signatures changed after administered metabolite exposure.
- Limitations
- The microbial conversion step was bypassed; this does not establish food-derived benefit.
- Evidence Source
- Bounded external search
- Reference
- [1]
- Study
- Urolithin A in Alzheimer-model mice.
- Population
- Urolithin A in Alzheimer-model mice.
- Result
- Learning/memory and mitophagy/lysosomal endpoints improved in the tested models.
- Effect / Magnitude
- Only extracted comparisons retained; no pooled effect or clinical-benefit magnitude assigned.
- Evidence Summary
- Learning/memory and mitophagy/lysosomal endpoints improved in the tested models.
- Limitations
- Not human cognition or a dietary polyphenol conversion intervention.
- Evidence Source
- Bounded external search
- Reference
- [3]
Human-donor faecal incubations converted epicatechin to phenolic intermediates and valerolactones with substantial donor-dependent rates and product profiles.
What this means
Epicatechin supplies a defined microbial substrate for phenolic ring-fission and valerolactone-generation capacity.
Evidence confidence: Not yet scored
Finding ID: PM6-F3
Finding Statement: Human-donor faecal incubations converted epicatechin to phenolic intermediates and valerolactones with substantial donor-dependent rates and product profiles.
Synthesised Evidence Confidence: Not yet scored
Synthesis: Human-donor faecal incubations converted epicatechin to phenolic intermediates and valerolactones with substantial donor-dependent rates and product profiles.
Synthesis Limitations: Donor cultures do not establish a predictable whole-food conversion yield, mitochondrial effect or clinical benefit. Human apple-extract evidence involves mixed monomeric catechins, not isolated epicatechin efficacy. Do not generalise to EGCG or all procyanidins. Numerical SEC remains pending full-method appraisal; no factor is forced.
Evidence Considered:
- Study
- Anaerobic epicatechin incubations with faecal inocula; LC-MS metabolite profiling.
- Population
- 24 healthy human donors; in-vitro microbial communities.
- Result
- Human-donor faecal incubations converted epicatechin to phenolic intermediates and valerolactones with substantial donor-dependent rates and product profiles.
- Effect / Magnitude
- No additional magnitude inferred.
- Evidence Summary
- Human-donor faecal incubations converted epicatechin to phenolic intermediates and valerolactones with substantial donor-dependent rates and product profiles.
- Limitations
- Donor cultures do not establish a predictable whole-food conversion yield, mitochondrial effect or clinical benefit. Human apple-extract evidence involves mixed monomeric catechins, not isolated epicatechin efficacy. Do not generalise to EGCG or all procyanidins.
- Evidence Source
- Bounded external search
- Reference
- [6]
5. BRS Pathways and Connections
5.1 BRS Pathways
No newly adjudicated pathway is established by this assessment.
5.2 Cross-BRS Mechanism Relationships
Existing connected mechanisms remain candidates in the review history; no new downstream admission is inferred.
5.3 Local BRS Mechanism Relationships
- BRS5-FM2-PM4 — Microbial Substrate-Processing Selection & Adaptation: related process for scope comparison; this link does not admit a newly characterised dependency.
7. Phenome Connections
These mappings are translational relationships, not single-mechanism outcome claims. Phenomes are emergent functional patterns supported by multiple interacting PMs across the BRAIN Framework.
Each Phenome relationship has two independent ratings. They are not combined or averaged.
Biology → Phenome Relationship Strength
How direct and important is this biological mechanism expected to be to the Phenome within the BRAIN model?
Evidence Confidence
How strongly does the adjudicated evidence support this particular biology → Phenome relationship?
No direct functional outcome relationship currently mapped.
8. References
- [1] Andreux et al. (2019) — Mitophagy Activator Urolithin a Is Safe and Induces a Molecular Signature
- [2] Singh et al. (2022) — Direct Supplementation with Urolithin a Overcomes Limitations of Dietary Exposure and Gut
- [3] Hou et al. (2024) — Urolithin a Improves Alzheimer's Disease Cognition and Restores Mitophagy and Lysosomal Functions
- [4] Schleupner & Carmichael (2022) — Closing Research Gaps Through Female Inclusion in Study Design
- [5] Selma et al. (2014) — Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species
- [6] Liu et al. (2020) — Interindividual Differences in Human Intestinal Microbial Conversion of (-)-Epicatechin to Bioactive Phenolic Compounds
No validated structured conversion route is currently projected for this PM. This does not remove or reclassify its existing dietary inputs.
Mapping state: admitted-food-targets-resolved.